NCT06214481View on ClinicalTrials.gov

A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

May 27, 2024

Study Completion Date

May 27, 2024

Conditions
Atopic Dermatitis
Interventions
DRUG

Rocatinlimab

Administered SC.

Trial Locations (1)

200040

Huashan Hospital Affiliated to Fudan University?, Shanghai

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT06214481 - A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter